We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The average annual percentage growth in the amount Americans spend on prescription drugs is expected to continue to decline over the next decade for a variety of reasons, including a decrease in the number of new drugs and in direct-to-consumer advertising, according to a report released last week by the Centers for Medicare & Medicaid Services (CMS).
The average annual percentage growth in the amount Americans spend on Rx drugs is expected to continue to decline over the next decade, according to a report released yesterday by the Centers for Medicare & Medicaid Services (CMS).
The General Accounting Office (GAO) expects at the end of March to issue its opinion on allegations the Bush administration violated the law by misusing taxpayer money in its advertising campaign for the new Medicare law, a GAO spokesperson said yesterday.
New Hampshire officials need to keep better track of whether drugmakers pay the rebates they owe on drugs covered by Medicaid, according to the HHS Office of Inspector General (OIG).
The FDA has banned dietary supplements containing ephedra because of safety concerns — a move that marks the first time the agency has exercised that authority under the 1994 Dietary Supplement Health and Education Act (DSHEA).
The Centers for Medicare & Medicaid Services (CMS) isn’t pursuing a wider agenda to curtail Medicare services of widespread, but unapproved, drug treatments despite considering of denying coverage for unapproved uses of two cancer drugs, an agency spokesman said.
Medicare and its beneficiaries could save nearly $700 million a year if the program’s reimbursement rates for three drugs — Lupron, albuterol and ipratropium bromide — were more in line with what purchasers pay to obtain them, according to the HHS Office of Inspector General (OIG).
California officials need to keep better track of the money that drugmakers owe as rebates on drugs covered by Medicaid, according to the HHS Office of Inspector General (OIG).
The Centers for Medicare & Medicaid Services (CMS) is considering denying coverage for unapproved uses of two cancer drugs, but an agency spokesman said Friday that the pending review is not part of a wider agenda to curtail Medicare coverage of widespread, but unapproved, drug treatments.
Drugmakers want to see changes to interim rules adopted last month for the transitional Medicare drug discount card that would ensure pricing information remains confidential, provide flexibility for off-label uses and allow appropriate coverage of first-in-class drugs, according to comments released by the Centers for Medicare & Medicaid Services (CMS) last week.